Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer.
D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D014508:Urea / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D003510:Cyclohexanes; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea; D005472:Fluorouracil